Oleandrin | 465-16-7

• 物质功能分类: 生物化工 - 中草药成分
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: Oleandrin
• 英文别名: [(3S,10S,13R,14S,16S,17R)-14-hydroxy-3-[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-16-yl] acetate
• CAS: 465-16-7；465-17-8；508-22-5；559-83-1；31087-94-2；144300-17-4
• 化学式: C₃₂H₄₈O₉
• 分子量: 576.728
• InChiKey: JLPDBLFIVFSOCC-KRNKPDPWSA-N

物化性质

• 熔点：
  250°C
• 比旋光度：
  D25 -48.0° (c = 1.3 in methanol)
• 沸点：
  557.17°C (rough estimate)
• 密度：
  1.26
• 溶解度：
  DMF：15 mg/ml； DMF:PBS (pH 7.2) (1:4)：0.2 mg/ml； DMSO：10 mg/ml；乙醇：5 mg/ml
• 颜色/状态：
  Crystals from ethanol
• 蒸汽压力：
  3.61X10-19 mm Hg at 25 °C (est)
• 稳定性/保质期：
  Stable under recommended storage conditions.
• 旋光度：
  Specific optical rotation: -48.0 deg at 25 °C/D (c= 1.3 in methanol)
• 分解：
  When heated to decomposition it emits acrid smoke and irritating fumes.
• 解离常数：
  pKa1: 6.8 (carboxy); pKa2: 13.2 (hydroxy); pKa3: 14.1 (secondary hydroxy) (est)

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  41
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  121
• 氢给体数：
  2
• 氢受体数：
  9

安全信息

• 危险品标志：
  T
• 安全说明：
  S22,S36/37/39,S45
• 危险类别码：
  R23/24/25
• WGK Germany：
  2,3
• 危险品运输编号：
  UN 2811
• RTECS号：
  FH4585000
• 危险标志：
  GHS06,GHS08
• 危险性描述：
  H300 + H330,H373
• 危险性防范说明：
  P260,P264,P284,P301 + P310,P310

制备方法与用途

概述

欧夹竹桃甙丙是一种具有观赏价值的常绿灌木或小乔木，属于欧夹竹桃甙丙科。尽管它因其毒性而闻名，是世界上最毒的植物之一，仍不时有报道指出人类和家畜因欧夹竹桃甙丙中毒导致死亡的情况。

生物活性

Oleandrin（PBI-05204、Foliandrin、Neriolin、Neriolostene、Folinerin、Corrigen、Neriolin）是Na+/K+-ATP酶的抑制剂，其IC50值为0.62 μM。此外，Oleandrin还能诱导细胞凋亡并减少人胶质瘤细胞的体外迁移。

靶点

Target	Value
Na+/K+-ATPase (Cell-free assay)	0.62 μM

化学性质

欧夹竹桃甙丙为白色晶体，可溶于甲醇、乙醇和DMSO等有机溶剂。这种物质来源于欧洲夹竹桃的叶子。

用途

欧夹竹桃甙丙具有强心和利尿的作用，并可用于含量测定、鉴定以及药理实验中。其主要药理作用包括强心和利尿。

分类 毒性分级

有毒物质

• 毒性等级: 剧毒
• 急性毒性 (静脉-猫): LD50 = 0.248毫克/公斤
• 可燃性危险特性: 可燃，火场排出辛辣刺激烟雾
• 储运特性: 库房低温通风干燥；密闭存放；与食品原料分开
• 灭火剂: 水、二氧化碳、干粉、砂土

以上信息有助于了解欧夹竹桃甙丙的相关特性和用途。

文献信息

• DEVICES AND AGENTS FOR DENERVATION
  申请人：Evans, Michael A.

  公开号：EP3246035A1

  公开（公告）日：2017-11-22

  Various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue.

  本文介绍了各种向肾神经局部输送药剂的输送装置。这些给药装置位于肾动脉内，并穿透肾动脉壁，将药剂输送到肾神经。输送装置可根据肾神经相对于肾动脉的纵向位置、径向位置和深度输送药剂。此外，还介绍了各种用于去神经支配、调节或以其他方式影响肾脏神经和其他神经组织的方法。此外，还介绍了用于去神经支配、调节或以其他方式影响肾脏神经和其他神经组织的各种药剂。
• COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF HEARING LOSS
  申请人：Zuo, Jian

  公开号：EP3618807A1

  公开（公告）日：2020-03-11
• Agents and methods for denervation
  申请人：EVANS Michael A.

  公开号：US20110182912A1

  公开（公告）日：2011-07-28

  Various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue.
• Methods and devices for denervation
  申请人：EVANS Michael A.

  公开号：US20110184337A1

  公开（公告）日：2011-07-28

  Various delivery devices are described to deliver an agent locally to the renal nerves. The delivery devices are positioned in the renal artery and penetrate into the wall of the renal artery to deliver the agent to the renal nerves. The delivery devices may be used to deliver the agent according to longitudinal position, radial position, and depth of the renal nerves relative to the renal artery. In addition, various methods are described to denervate, modulate, or otherwise affect the renal nerves and other neural tissue. Also, various agents are described to denerve, modulate, or otherwise affect the renal nerves and other neural tissue.
• Compositions and Methods for the Prevention and Treatment of Hearing Loss
  申请人：Ting Therapeutics LLC

  公开号：US20220133730A1

  公开（公告）日：2022-05-05

  Method, kit and pharmaceutical compositions using an inhibitor of EGFR signaling for prevention or treatment of hearing loss are described.